Small molecule · Inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) · developed by Glaxosmithkline
Momelotinib is an orally available small molecule kinase inhibitor that blocks wild-type JAK1 and JAK2 as well as the mutant JAK2 V617F, reducing JAK-STAT signaling. It also inhibits ACVR1 (ALK2), which lowers hepcidin expression and increases iron availability for red blood cell production. It is used in myelofibrosis, including primary and secondary forms in adults with anemia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04173494 | Phase 3 | Primary Myelofibrosis | Completed | GSK |
| NCT02515630 | Phase 2 | Primary Myelofibrosis (PMF) | Completed | GSK |
| NCT02258607 | Phase 1 | Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer | Terminated | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Post-Essential Thrombocythemia MyelofibrosisPost-polycythemia Vera (Post-PV) MyelofibrosisPost-Polycythemia Vera MyelofibrosisPostessential Thrombocythemia (Post-ET) MyelofibrosisPrimary MyelofibrosisPrimary Myelofibrosis (PMF)
Updated Nov 15, 2026. Something wrong or missing? Report it on the GSK page.
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →